Concepedia

Author

Helle Toldbod

Aarhus University Hospital

Also Known As

H Toldbod, H. E. Toldbod, H. Toldbod, Helle E. Toldbod, Helle Erbs Toldbod, Helle Toldbod, Toldbod, H, Toldbod, Helle, Toldbod, Helle Erbs

32

Publications

1.2K

Citations

11

H-Index

8

Concepts

All Affiliations

Aarhus University HospitalRigshospitaletSt Olav's University HospitalHelsinki University HospitalUppsala University Hospital
HT

About

Helle Toldbod is an author at Aarhus University Hospital specializing in radiation oncology, pathology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

145

2

Medicine

1

1

145

3

Immunology

1

1

145

4

Pathology

1

1

145

5

Hematology

1

1

145

Helle Toldbod

×

12

Publications

1.1K

Citations

10

H-Index

YearCitations

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Francesco d’Amore, Thomas Relander, Grete F. Lauritzsen,

Journal of Clinical Oncology

2012

584

Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer

Anne Birgitte Als, Lars Dyrskjøt, Hans von der Maase,

Clinical Cancer Research

2007

205

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings,

The Lancet Haematology

2018

145

Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts

Anne Sofie Brems-Eskildsen, Karsten Zieger, Helle Toldbod,

BMC Cancer

2010

66

Potent Influence of Bovine Serum Proteins in Experimental Dendritic Cell‐Based Vaccination Protocols

Helle Toldbod, Ralf Agger, Lars Bolund,

Scandinavian Journal of Immunology

2003

36

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d’Amore, Sirpa Leppä, María Gomes da Silva,

Blood

2018

26

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

David Lewis, Mats Jerkeman, Lexy Sorrell,

Blood

2024

18

Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial

Mats Jerkeman, Martin Hutchings, Riikka Räty,

Blood

2016

17

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, Gerald Wulf, Lorenz Truemper,

Blood

2018

16

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Francesco d’Amore, Sirpa Leppä, María Gomes da Silva,

Blood

2012

12

Page 1